For the year ending 2025-12-31, OVID had -$13,148K decrease in cash & cash equivalents over the period. -$38,334K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -17,414 |
| Change in fair value of royalty monetization liability | 0 |
| Unrealized gain on equity investments | 21,052 |
| Change in accrued interest and accretion of discount on marketable securities | -695 |
| Stock-based compensation expense | 4,807 |
| Depreciation and amortization expense | 273 |
| Noncash operating lease expense | 1,187 |
| Change in lease liability | -1,336 |
| Prepaid expenses and other current assets | 1,802 |
| Accounts payable | -1,234 |
| Accrued expenses | -1,068 |
| Net cash used in operating activities | -38,334 |
| Purchase of marketable securities | 91,854 |
| Sales/maturities of marketable securities | 42,000 |
| Purchases of property and equipment | 0 |
| Software development and other costs | 0 |
| Net cash (used in) provided by investing activities | -49,854 |
| Proceeds from private placement financing, net of transaction costs | 75,116 |
| Proceeds from exercise of options and employee stock purchase plan | 91 |
| Net cash provided by financing activities | 75,207 |
| Effect of exchange rates on cash, cash equivalents and restricted cash | -167 |
| Net decrease in cash, cash equivalents and restricted cash | -13,148 |
| Cash, cash equivalents and restricted cash, at beginning of period | 28,232 |
| Cash, cash equivalents and restricted cash, at end of period | 15,084 |
Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc. (OVID)